Summary
Cencora, Inc. (COR) reported a significant decline in net income for the quarter ended March 31, 2019, primarily due to a substantial $570 million impairment charge related to long-lived assets at its PharMEDium subsidiary. While revenue increased by 5.6% year-over-year to $43.3 billion, driven by growth in the Pharmaceutical Distribution Services segment, the substantial impairment charge overshadowed this top-line growth. Despite the net income drop, the company's core distribution business demonstrated resilience. The report also highlights the ongoing complexities of legal matters, particularly opioid-related lawsuits, and the successful resolution of certain antitrust litigation, which provided a notable gain. Investors should monitor the ongoing resolution of the PharMEDium situation and potential future impacts of legal liabilities.
Financial Highlights
56 data points| Revenue | $43.32B |
| Cost of Revenue | $41.89B |
| Gross Profit | $1.42B |
| SG&A Expenses | $628.04M |
| Operating Income | $47.56M |
| Net Income | $27.14M |
| EPS (Basic) | $0.13 |
| EPS (Diluted) | $0.13 |
| Shares Outstanding (Basic) | 210.93M |
| Shares Outstanding (Diluted) | 212.56M |
Key Highlights
- 1Revenue increased by 5.6% to $43.3 billion for the quarter ended March 31, 2019, compared to the prior year period, driven by the Pharmaceutical Distribution Services segment.
- 2A significant impairment charge of $570.0 million related to long-lived assets at PharMEDium negatively impacted operating income and net income.
- 3Operating income decreased by 90.1% to $47.6 million, largely due to the aforementioned impairment charge.
- 4Net income attributable to AmerisourceBergen Corporation decreased substantially to $27.1 million from $287.5 million in the prior year quarter.
- 5Gains from antitrust litigation settlements provided a significant boost to gross profit, totaling $52.0 million for the quarter.
- 6The company continues to manage various legal matters, including ongoing opioid-related lawsuits, with no material adverse outcome currently estimated, though significant uncertainties remain.
- 7Cash provided by operating activities for the six months ended March 31, 2019, was $1.1 billion, a significant improvement from the prior year's comparable period which used $77.2 million.